During skeletal muscle regeneration, muscle stem cells (MuSCs) respond to multiple signaling inputs that converge onto mammalian target of rapamycin complex 1 (mTORC1) signaling pathways. mTOR function is essential for establishment of the differentiationcommitted progenitors (early stage of differentiation, marked by the induction of myogenin expression), myotube fusion, and, ultimately, hypertrophy (later stage of differentiation). While a major mTORC1 substrate, p70S6K, is required for myotube fusion and hypertrophy, an mTORC1 effector for the induction of myogenin expression remains unclear. Here, we identified Per-Arnt-Sim domain kinase (PASK) as a downstream phosphorylation target of mTORC1 in MuSCs during differentiation. We have recently shown that the PASK phosphorylates Wdr5 to stimulate MuSC differentiation by epigenetically activating the myogenin promoter. We show that phosphorylation of PASK by mTORC1 is required for the activation of myogenin transcription, exit from self-renewal, and induction of the myogenesis program. Our studies reveal that mTORC1-PASK signaling is required for the rise of myogenin-positive committed myoblasts (early stage of myogenesis), whereas mTORC1-S6K signaling is required for myoblast fusion (later stage of myogenesis). Thus, our discoveries allow molecular dissection of mTOR functions during different stages of the myogenesis program driven by two different substrates.
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mTOR | PASK | myogenin | muscle stem cell | Pax7 S keletal muscle has a remarkable ability to restore its form and function following nearly complete myofiber destruction due to injury (1) . This regenerative potential of skeletal muscle is largely attributed to its resident muscle stem cells (MuSCs) (2) . MuSCs occupy a specific niche in the basal lamina, which supports their metabolic and cell cycle quiescence in uninjured muscle. Upon injury to myofibers, disruption of the niche triggers the activation of transcriptional, metabolic, and signaling events within MuSCs resulting in cell division. The progenies of these proliferative cells ultimately undergo myogenic differentiation and fuse to regenerate the multinuclear myofibers (2) (3) (4) .
Regenerative myogenesis is a well-coordinated program that involves the sequential action of multiple transcription factors working in concert with epigenetic regulators. Following an injury, quiescent paired box 7-positive (Pax7 + ) MuSCs begin to proliferate, and a subset of these MuSCs gain expression of the basic helix-loop-helix transcription factor MyoD. Myogenin (MyoG) is a transcriptional target of MyoD, and MyoD
+

/MyoG
+ cells form differentiation-committed myoblasts and initiate the myoblast fusion program. Thus, induction of Myog expression is a key, irreversible step that establishes the myogenesis program. Thus, to ensure precise regulation of the Myog promoter activation, the epigenetic regulators, such as histone methyltransferases, demethylases, histone acetyltransferases, and deacetylases, establish the framework for MyoD transcriptional function (5) (6) (7) . In particular, histone H3 lysine 4 methyltransferase activities of the mixed lineage leukemia (MLL) enzymatic complexes are required for activation of the Myog locus during myogenesis (3, 8, 9) . However, it remains incompletely understood how diverse niche-derived signaling cues impinge upon MLL complexes to regulate transcriptional activation of the Myog promoter.
Niche-derived signaling cues, such as Wnt, insulin, insulinlike growth factors (IGFs), and nutrients, are known to regulate MuSC activation, proliferation, commitment, and execution of the myogenesis program (10) (11) (12) . The establishment of myogenic commitment is regulated by the PI3K/Akt, mammalian target of rapamycin (mTOR), MAPK, and β-catenin signaling pathways (11, 13, 14) . Of these, the mTOR protein kinase is unique in that it can be activated by nutrients and diverse signaling cues present in the regenerating niche (14) (15) (16) (17) . This kinase exists in two functionally distinct complexes, the raptorcontaining mTOR complex 1 (mTORC1) and the rictorcontaining mTOR complex 2 (mTORC2) (18) . The loss of mTOR inhibits both MuSC proliferation and differentiation (16) , and this appears to be mostly explained by the loss of the raptor-containing mTORC1 (19) . The genetic ablation of rictor in MuSCs, however, appears to be well tolerated, although it may affect MuSC lineage specification (20) . In addition to its Significance Skeletal muscle harbors a robust, yet quiescent stem cell population. These stem cells are activated upon myofiber injury to repair damaged myotome. This regenerative myogenesis is guided by external signaling cues that allow stem cells to acquire various stem cell fates. Here, we describe a growth factor and nutrient-stimulated pathway, whereby mammalian target of rapamycin (mTOR) activates Per-Arnt-Sim domain kinase (PASK) protein kinase in muscle stem cells. This mTOR-dependent activation of PASK is required for the transcriptional induction of the myogenin gene and subsequent terminal differentiation program. Finally, our results suggest that mTOR-PASK and mTOR-S6 Kinase signaling are required for distinct stages of myogenesis program, and link nutrient environment to early stages of the myogenesis program.
function in regenerative myogenesis, mTORC1 was implicated recently in inducing a G alert state in MuSCs. G alert is a quasiactivated state of MuSCs in an uninjured, contralateral leg in response to a muscle injury in a distinct leg (17) . MuSCs in the G alert state showed faster cycling times and increased Myog expression. Thus, mTORC1 is critical for MuSC activation and regenerative myogenesis in response to injury. However, despite its importance, it remains unclear how mTORC1 signals to activate the myogenic transcriptional network.
We have recently identified a signaling pathway downstream of the Per-Arnt-Sim domain kinase (PASK) protein kinase, which connects signaling cues to the phosphorylation of Wdr5, a member of MLL, SET1, and other histone-modifying enzymatic complexes, to drive transcriptional activation of Myog and myogenesis (21) . Our data show that PASK, via Wdr5 phosphorylation, collaborates with MyoD for transcriptional activation of Myog to drive the myogenesis program (21) . Thus, we hypothesized that PASK and Wdr5 are intermediates of the signaling pathways that drive myogenesis (21) . However, it remained unclear how differentiation signaling cues might activate the PASK-Wdr5 pathway. Here, we identify PASK as an interacting partner and a direct substrate of mTORC1 that is a necessary mediator of its myogenic function. Our data suggest that mTORC1 connects nichederived nutrient sufficiency and hormonal signals to epigenetic complexes such as MLL via PASK phosphorylation to drive MuSC differentiation.
Results
Nutrients and Insulin Activate PASK in an mTORC1-Dependent Manner. We have previously reported that PASK expression was induced several-fold upon skeletal muscle injury and that loss of PASK resulted in severe defects in muscle regeneration (21) . We showed that PASK activity was also posttranslationally stimulated during in vitro myogenesis (21) . To understand if this activation of PASK is required for its prodifferentiation functions, we first asked if PASK is similarly activated during muscle regeneration in vivo. To do so, we generated mice expressing V5-tagged human PASK (hPASK) from the Rosa26 locus (termed Rosa26 hPASK-V5 ). Parenthetically, probably due to the requirement of posttranslational activation, overexpression of hPASK in mice did not result in any overt skeletal muscle phenotype in uninjured animals. However, during regeneration, Rosa26 hPASK-V5 mice showed significantly elevated mRNA and protein levels of MyoG and its target myosin heavy chain (Myh3) (SI Appendix, Fig. S1 A and B) compared with Rosa26 control mice. Strikingly, isolated, and hence activated, MuSC pools derived from the Rosa26 hPASK-V5 mice showed an increased propensity to differentiate in normal growth media as early as 1 d after isolation in culture media, whereas WT MuSCs remained mononucleated for up to at least 2 d (SI Appendix, Fig. S1C ). Using this PASK allele, which is not subjected to transcriptional regulation [SI Appendix, Fig. S1A ; compare hPASK vs. mouse PASK (mPASK) mRNA levels], we measured PASK kinase activity during tibialis anterior (TA) muscle regeneration. As shown in Fig. 1A , PASK activity, as assessed by autophosphorylation Fig. 1 . Nutrient and insulin signaling activates PASK via mTORC1. (A) PASK is activated during skeletal muscle regeneration. TA muscles were isolated from control or BaCl 2 -injured Rosa26 hPASK-V5 mice 3 d postinjury (DPI). V5-tagged PASK was immunoprecipitated from tissue extract to assay PASK activation by an in vitro autophosphorylation assay, which indicates the incorporation of 32 P into PASK as a function of kinase activity. An immunoblot (IB) of MyoG marks myogenic regeneration. IP, immunoprecipitation. (B) CHO-K1 cells expressing V5-tagged hPASK were stimulated with 100 nM insulin for the indicated times. PASK was immunoprecipitated using anti-V5 antibody, and an in vitro kinase assay was performed as in A. Activation of PI3K and mTORC1 signaling was demonstrated by the appearance of phospho-AKT and phospho-S6K. (C) HEK293E cells were starved of amino acids and glucose for 8 h, followed by stimulation with either 25 mM glucose or 800 μM L-leucine for 1 h. Endogenous PASK was purified using anti-PASK antibody from cell extracts, and in vitro kinase activity assay was performed as in A. (D) PASK from HEK293E cells was assayed as in C. Cells were stimulated with 100 nM insulin for 1 h after pretreatment with DMSO, 100 nM rapamycin, or 25 μM 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Endogenous PASK was purified using anti-PASK antibody from cell extracts, and an in vitro kinase activity assay was performed as in A. (E) Quantification of D. Phospho-PASK ( 32 P-PASK) and total PASK from three independent experiments; the ratio was expressed as the fold change in PASK activity under the indicated stimuli. Error bars are ± SD. *P < 0.05; **P < 0.01. HG, high glucose; LG, low glucose. (F) V5-PASK was expressed in Tsc2 −/− cells with or without complementation with WT hTsc2. Cells were serumstarved overnight and then stimulated with 100 nM insulin for 1 h. PASK was immunoprecipitated using anti-V5 antibody, and an in vitro kinase assay was performed. The yeast Ugp1 protein, which is robust in an in vitro substrate of PASK, was used as an exogenous substrate. (G) PASK was purified from HEK293T cells with expressing vector control (−) or Rheb Q64L and subjected to kinase activity assay as in F. (H) HEK293E cells were transfected with control or mTOR-targeting siRNA for 24 h. A vector expressing V5-PASK was then transfected; after 24 h, cells were serum-starved overnight and then stimulated with 100 nM insulin for 1 h. PASK was purified and subjected to a kinase activity assay as in F. (I) Primary myoblasts isolated from Rosa26 hPASK-V5 mice were transfected with control or mouse Tsc2-targeting siRNA. Twenty-four hours after transfection, cells were switched to 5% serum-containing medium overnight, followed by 4 h of total serum starvation. Cells were then treated with vehicle or 100 nM insulin for 1 h. PASK was then purified and subjected to kinase activity assay as in F. (J) Quantification of PASK kinase activity measurements from three experiments as in I. *P < 0.05; ***P < 0.005. (21, 22) , was induced 3 d after injury. The increase in PASK activity coincided with the time point when both MyoG and endogenous mouse PASK expression is induced (Fig. 1A and SI Appendix, Fig. S1A ).
To understand how niche signals, like nutrients and insulin, activate PASK during muscle regeneration, we examined PASK activation by these stimuli in a cell-autonomous manner. As shown in Fig. 1B , PASK was acutely and transiently activated by insulin stimulation in CHO-K1 cells. Similarly, glucose and amino acids such as L-leucine also activate PASK in HEK293E cells (Fig. 1C) . While glucose activated PASK modestly but consistently, we observed a strong increase in PASK activity upon addition of L-leucine to cell culture media (Fig. 1C) . Since mTORC1 is a convergence point in both insulin and amino acid signaling (23), we asked if the mTORC1 activity is required for PASK activation. As shown in Fig. 1C , the addition of the mTORC1 inhibitor rapamycin (24) completely blocked PASK activation by glucose and L-leucine.
To further explore the role of mTORC1 in the regulation of PASK activity downstream of nutrient and insulin stimulation, we analyzed PASK activity in the presence or absence of kinase modulators that either augment or inhibit mTORC1 activity. AMP-activated protein kinase (AMPK) is a negative regulator of mTORC1 kinase function (25) . As shown in Fig. 1 D and E, insulin activated PASK in the presence of either low or high glucose, and this was suppressed by pretreatment with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide to an extent similar to rapamycin treatment. AMPK phosphorylates and activates Tsc2, which negatively regulates mTORC1 function (26) . Consistent with that, Tsc2 −/− mouse embryonic fibroblasts (MEFs), complemented with empty vector control but not with human Tsc2 (27) , showed mTORC1 hyperactivation, as evidenced by increased phosphorylation of the mTORC1 substrate p70S6K (Fig. 1F) . Loss of Tsc2 also increased PASK kinase activity, as shown by increased in vitro autophosphorylation and phosphorylation of its heterologous substrate Ugp1 (28) (Fig. 1F) . Tsc2 functions as a GTPase-activating protein (GAP) for the Rheb GTPase, which stimulates mTORC1 activity (29) . Expression of a constitutively activated Rheb (Rheb Q64L ), which hyperactivates mTORC1, also resulted in increased PASK activity (Fig.  1G ). On the other hand, silencing mTOR resulted in a nearcomplete block of insulin-stimulated PASK activation (Fig. 1H) .
Finally, to test whether mTORC1 contributes to PASK activation in MuSCs, we isolated MuSCs from Rosa26 hPASK-V5 mice and assessed PASK activation by insulin after silencing Tsc2. During MuSC isolation, PASK was activated modestly, but it was further activated by insulin stimulation ( Fig. 1 I and J) . This modest activation of PASK may account for the increased propensity of MuSCs derived from transgenic mice observed in SI Appendix, Fig. S1C . The loss of Tsc2 further activated PASK in the presence or absence of insulin. Thus, our results demonstrate that the mTORC1 complex activates PASK in response to insulin and nutrient signaling.
PASK Is Phosphorylated by mTORC1 at Multiple Residues to Stimulate
Its Activity. We hypothesized that mTORC1-dependent phosphorylation of one or more residues on PASK might result in its activation by nutrients and insulin. Therefore, we performed metabolic in-cell labeling using radioactive ( 32 P) phosphate in Tsc2 −/− or human Tsc2 (hTsc2)-complemented Tsc2 −/− MEFs in the presence or absence of rapamycin. As shown in Fig. 2A , endogenous PASK derived from Tsc2 −/− MEFs showed significantly increased phosphorylation compared with hTsc2-complemented cells. Furthermore, this increase in PASK phosphorylation was partially suppressible by low-dose rapamycin, consistent with some other mTORC1 substrates (30) (Fig. 2A) . We also tested if, similar to PASK activity (Fig. 1G ), PASK phosphorylation was induced by constitutively activated Rheb (Rheb Q64L ) and if that is dependent upon the catalytic activity of PASK. As shown in Fig. 2B , both WT and kinase-dead (KD) PASK showed enhanced in-cell phosphorylation in the presence of Rheb Q64L . In contrast, the phosphorylation of PDK1, an upstream activator of Akt that is not an mTORC1 substrate, was not induced by Rheb coexpression. Thus, mTORC1 activation induces the phosphorylation of PASK in cells, and the increased PASK phosphorylation is independent of its own catalytic activity, demonstrating that autophosphorylation is not required.
To identify residues on PASK that are specifically targeted by mTORC1 activity, we performed a domain truncation analysis in the presence or absence of Rheb Q64L and rapamycin (Fig. 2C ). Rheb stimulated PASK phosphorylation within both the Cterminal kinase domain-containing region that includes residues 941-1,323 and the N-terminal fragment that contains the first 738 residues (Fig. 2D) . Surprisingly, these two regions showed differences in sensitivity to rapamycin inhibition, as the ΔC fragment (residues 1-738) showed much more rapamycin sensitivity than the ΔN fragment (residues 941-1,323; Discussion). Using mass spectrometry (SI Appendix, Table S1 ), bioinformatics, and site-directed mutagenesis ( Fig. 2E and SI Appendix, Fig. S2 A and B), we identified two clusters of sites that were hyperphosphorylated upon mTORC1 activation. The sites within the N-terminal fragment include Thr 640 and Thr
642
( Fig. 2E ), which showed a marked similarity to rapamycinsensitive sites on another mTORC1 substrate, Grb10 ( (Fig. 2G ), thus confirming these five sites as targets of mTORC1-stimulated phosphorylation and its effect on PASK activity described in Fig. 1 . mTORC1 activates multiple kinases within the AGC family of protein kinases, such as Akt, p70S6K, and p90RSK. However, our data show that pretreatment with the mTOR inhibitor torin, but not p70S6K inhibitor (PF408671) or pan-AGC kinase inhibitor (AT13148), abolished Rheb-stimulated PASK phosphorylation (Fig. 2H) . Interestingly, the sequence surrounding the Rheb-stimulated PASK phosphorylation sites appears similar to many of the recently identified mTORC1 substrates (30) (Fig.  2E ). To test if mTORC1 can directly phosphorylate these sites, we performed an in vitro kinase assay using purified mTORC1 in the presence of activated Rheb. We used KD PASK to avoid background phosphorylation of WT PASK, which could be further confounded by an increase in its activity upon mTOR phosphorylation. As shown in Fig. 2I , KD PASK was robustly phosphorylated in vitro by purified mTORC1. Mutation of two N-terminal phosphorylable residues (T 640 AT 642 A) only modestly lowered mTORC1 phosphorylation of PASK, and mutation of all five phosphorylation sites was required for complete loss of mTORC1-mediated phosphorylation of PASK. We also utilized a mutagenized peptide array system that was used to identify novel mTORC1 substrates as previously described (30) to pinpoint residues targeted by mTORC1. The mutated peptide library was generated by mutating phosphorylable residues within each peptide, except the phosphorylatable residue at position 0 (indicated by the asterisk in SI Appendix, Fig. S2C) . These peptides were then used as substrates for in vitro kinase reactions with purified mTORC1. As shown in SI Appendix, Fig. S2 D and E, a peptide representing Thr 640 /Thr 642 showed strong phosphorylation that could be abrogated by mutation of Thr 640 (in the site A sequence). Site B was used as a negative control, being a poor mTORC1 substrate in our experiments. On the other hand, site C peptide showed robust phosphorylation by mTORC1, and mutation of Ser 949 was sufficient to significantly diminish mTORC1-mediated phosphorylation of this peptide (SI Appendix, Fig. S2 B and C) in vitro. Thus, our data suggest that mTORC1-mediated phosphorylation of PASK at multiple residues is required for nutrient and insulin signaling to activate PASK.
PASK Forms a Nutrient-Sensitive Complex with mTORC1. To understand the mechanistic basis whereby PASK is phosphorylated and activated by mTORC1, we sought to understand whether PASK associates with mTOR or any of its associated complex 1 proteins. We first immunoprecipitated V5-tagged WT PASK or a K1028R mutant lacking kinase activity (KD) from cells that coexpress either Myc-tagged WT mTOR or a D2357E/V2364I mutant lacking kinase activity (KD). Both WT and KD PASK could be immunoprecipitated with either the WT or KD version of mTOR (Fig. 3A) . Interestingly, the WT PASK associated with KD mTOR showed significantly diminished phosphorylation at Thr 307 , which is an autophosphorylation site that we have shown previously to be a reliable marker of PASK activity (31) . Thus, expression of KD mTOR suppresses PASK activity in a dominant negative manner in cells. When endogenous mTOR was isolated from cells, PASK was copurified in addition to the members of the mTORC1 complex (Fig. 3B) . Similarly, immunoprecipitation of PASK-V5 copurified endogenous mTOR and raptor (Fig. 3C) . When mTOR was silenced, the association of PASK with mTOR and raptor was significantly reduced, suggesting that the PASK-raptor association is likely mediated by mTOR. Using domain truncation analysis, we found that the Cterminal residues 941-1,323 in PASK, which include the kinase domain and surrounding regions, are necessary to interact with endogenous mTORC1 (Fig. 3D) . Finally, we found that a mixture of L-leucine and L-arginine, two of the stimuli that led to phosphorylation and activation of PASK, as well as expression of Rheb Q64L , weakens the PASK-mTOR association (Fig.  3E) . Thus, PASK appears to form a nutrient and signalingsensitive complex with mTORC1, similar to what was previously reported for the mTOR-raptor association (32) . These data suggest that PASK dynamically associates with mTORC1, whereby mTOR directly phosphorylates and activates PASK, resulting in its release from the complex. that regulate myogenesis (34) . As a tissue with significant metabolic demand, skeletal muscle homeostasis is tightly linked to nutrient status. This is consistent with the fact that the nutrient-responsive mTORC1 has been shown to regulate myogenesis and myofiber hypertrophy (14-16, 23, 35) although its downstream effectors remain unknown (14) . Because mTORC1 activates PASK and we previously demonstrated that PASK is required for efficient damage-induced myogenesis (21), we asked if mTORC1 and PASK functions converge on a specific mechanism to regulate the myogenesis program. We compared myogenic induction upon loss of PASK and mTORC1 signaling in both MuSCs and C2C12 myoblasts. As shown in SI Appendix, Fig. S4 A and B, both mTORC1 and PASK inhibition (with rapamycin and BioE-1197, respectively) effectively and similarly suppressed MyoG + conversion and myoblast fusion in isolated MuSCs. This failure to convert to MyoG + cells appears to be due to impaired induction of Myog mRNA in the presence of the inhibitors (SI Appendix, Fig. S4C ). To determine specifically how mTORC1 activation affects myogenesis and what role PASK plays in that process in primary myoblasts, we silenced Tsc2 in isolated primary myoblasts and analyzed the mRNA levels of Pax7, Myog, and Acta1, which mark proliferating, committed, and differentiated stages, respectively. As shown in SI Appendix, Fig. S4D , loss of Tsc2 resulted in a modest but significant decrease in Pax7 mRNA and an increase in Myog mRNA, suggesting mTORC1 activation increases terminal differentiation commitment. This is further evidenced by increased expression of the muscle-specific actin Acta, which marks terminally differentiated myocytes. Pretreatment with PASK inhibitor (BioE-1197) or mTORC1 inhibitor (rapamycin) resulted in a significant increase in mRNA levels for Pax7, regardless of Tsc2 status. Modest, but significant increase in the mRNA levels of Myog and Acta1 as seen in Tsc2 silenced control myoblasts, was absent when PASK or mTORC1 was inhibited (SI Appendix, Fig. S4D ).
We next sought to identify components of the mTORC1 and mTORC2 complexes that are necessary for MyoG expression and myogenesis. To do so, we silenced mTOR, raptor (member of mTORC1), rictor (member of mTORC2), or the mTORC1 substrate p70S6K (major substrate of mTORC1) or PASK during insulin-stimulated myogenesis of cultured myoblasts (C2C12). Consistent with a previous report (19) , mTORC1, but not mTORC2, is required for MyoG protein expression as loss of raptor, but not rictor, suppressed MyoG induction (Fig. 4A) .
Furthermore, silencing of PASK, but not p70S6K, suppressed MyoG expression, suggesting that mTORC1-PASK, but not mTORC1-S6K, signaling is required for induction of the terminal differentiation program. These results in cultured myoblasts recapitulated our above-described findings indicating a common role of mTORC1 and PASK in the control of MyoG expression ( Fig. 4A and SI Appendix, Fig. S4 ). However, the mTORC1 is a well-established determinant of skeletal muscle hypertrophy in various animal models, a function that is largely mediated by its substrate p70S6K. To functionally compare mTOR-PASK and mTOR-S6K signaling during myogenesis, we set up a temporal inhibition experiment in which mTORC1, PASK, or p70S6K was inhibited using rapamycin, BioE-1197, or PF408671, respectively, before differentiation initiation (pretreatment at day −1, Fig. 4B ) or after differentiation initiation (treatment at day +1, Fig. 4D ) in C2C12 cells. Inhibition of mTORC1 and PASK, but not p70S6K, significantly suppressed the rise in MyoG + cell numbers [ Fig. 4 B and C, Right (quantified in the latter)]. However, despite normal induction of the MyoG, p70S6K inhibition abrogated the myoblast fusion to the similar extent as mTORC1 or PASK inhibition [ Fig. 4 B and C, Left (quantified in the latter)]. Hence, we hypothesized that mTORC1-PASK signaling might be required for MyoG expression and mTORC1-S6K signaling may drive the myoblast fusion event. To test this hypothesis, we stimulated a differentiation program and added mTOR, PASK, or p70S6K inhibitor after 24 h of differentiation (treatment on day +1, Fig. 4D ). When imaged at day +3, we noticed that inhibition mTORC1 and PASK modestly (still significantly) affected MyoG expression, whereas MyoG + cell numbers were comparable in both control and S6K1-inhibited samples [ Fig. 4 D and E, Right (quantified in the latter)]. Interestingly, while PASK inhibition only modestly blocked myoblast fusion, inhibition of mTORC1 and S6K nearly completely blocked the fusion program, despite the overall increase in MHC + myofiber numbers [ Fig. 4 D and E, Left (quantified in the latter)]. These results suggest a distinct pathway downstream of mTORC1 during myogenesis, in that mTORC1-PASK signaling drives MyoG expression, whereas mTORC1-S6K signaling is required for the myoblast fusion program. by increased MyoG staining (SI Appendix, Fig. S5 A and B) and fusion index (percentage of nuclei inside myotubes/total number of nuclei; SI Appendix, Fig. S5 C and D) . Rapamycin treatment effectively reversed this increase in myogenesis in PASKoverexpressing MuSCs (SI Appendix, Fig. S5 ). We reasoned that since rapamycin is able to suppress myogenesis in MuSCs from Rosa26 hPASK-V5 mice, mTORC1 is likely already activated during isolation of MuSCs. Therefore, Tsc2 silencing should not have an additive effect on myogenesis. Consistent with that, while the activation of the mTORC1 pathway by Tsc2 silencing resulted in modest stimulation of myogenesis in control cells (SI Appendix, Fig. S5 ), MuSCs from Rosa26 hPASK-V5 mice did not show further enhancement of myogenesis. Again, rapamycin treatment inhibited myogenesis regardless of PASK overexpression, suggesting the requirement for activated mTORC1 in inducing myogenesis downstream of PASK. Based on these data, and on the fact that BioE-1197 treatment effectively blocked myogenesis downstream of Tsc2 knockdown (SI Appendix, Fig. S4D ), we hypothesize that mTOR activation of PASK is required for induction of the myogenesis program.
To test this hypothesis, we retrovirally expressed vector control, WT, KD, or TS [5] A-mutated PASK in isolated MuSCs from PASK −/− mice. As shown in Fig. 5A , the reexpression of WT, but not KD, PASK fully restored MyoG and MHC expression in isolated PASK −/− MuSCs. Expression of TS [5] A-mutated PASK, on the other hand, had very modest effects on MyoG and MHC (Fig. 5A) . We also utilized the CRISPR/Cas9 system to delete endogenous mouse PASK in C2C12 myoblasts (Crispr PASK ) and reconstituted with either GFP vector or WT, KD, or TS [5] Amutated PASK. Using these cell lines, we assayed the effectiveness of myogenesis in response to insulin. Expression of WT, but not KD PASK, resulted efficient rescue of the number of MyoG + cells in Pask deleted C2C12 cells (Fig. 5 B and C) . Expression of TS [5] A-mutated PASK only modestly rescued the defect in MyoG + cell number compared with WT PASKexpressing cells (Fig. 5 B and C) . Similarly, expression of WT PASK resulted in full restoration of myogenesis, as measured by the fusion index formation (Fig. 5 D and E) . In contrast, cells expressing TS [5] A mutant PASK were defective in forming multinucleated myotubes compared with WT PASK-expressing cells (Fig. 5 D and E) . We think this defect in the TS [5] A mutant in the later phase of myogenesis is attributable to an overall decline in the number of MyoG + cells that are available for fusion. Thus, despite PASK not being critically required for the later phase of myogenesis (myonuclear fusion) once MyoG is sufficiently induced (Fig. 4 B-E) , our data suggest that mTORC1 phosphorylation of PASK might be required for generating a sufficient MyoG + myoblast population that can undergo myonuclear fusion to replenish myofibers. mTOR-PASK-Wdr5 Forms a Signaling Cascade to Regulate the Onset of the Myogenesis Program. We have previously shown that phosphorylation of Wdr5 is necessary and sufficient for the effects of PASK to induce Myog transcription and myogenesis (21) . Moreover, the physical interaction between PASK and Wdr5 was specifically induced upon insulin treatment to initiate myogenesis (21) . Herein, we showed that insulin treatment also stimulated PASK phosphorylation and activation in an mTORC1-dependent manner. Hence, we hypothesized that mTORC1 activation might enhance the PASK-Wdr5 association. To test this, we coexpressed WT or KD PASK with WT-Wdr5 in the presence or absence of Rheb Q64L and measured the PASK-Wdr5 association. As expected, expression of Rheb Q64L caused increased WT PASK in vivo activity as measured by autophosphorylation at Thr 307 (Fig. 6A) . Activation of mTOR also stimulated interaction between PASK and Wdr5, regardless of PASK activity status (WT vs. KD PASK). Interestingly, the C-terminal residues where mTORC1 phosphorylates PASK are adjacent to the Wdr5 binding region in PASK that we identified previously (21) (Fig. 6B) . To more precisely map the Wdr5 binding region in PASK, we mutagenized the conserved residues within this stretch and examined effects on the interaction with Wdr5 (Fig. 6C) . As shown in Fig. 6D , mutation of Twenty-four hours following differentiation, at day +1, cells were fixed with 4% paraformaldehyde and the induction of the myogenesis program (by antimyogenin staining) and myoblast fusion (by anti-MHC staining) was quantified (in D). ***P < 0.005 (control vs. inhibitors). NS, not significant vs. control.
(D and E) C2C12 cells were allowed to attain confluency and induced for differentiation in the absence of inhibitors. Twenty-four hours following differentiation, at day +1, cells were treated with 100 nM rapamycin, 50 μM BioE-1197, or 40 μM S6Ki in differentiation media. Cells were fixed at day 3, and induction of the myogenesis program (by antimyogenin staining) and myoblast fusion (by anti-MHC staining) was measured and quantified (in E). *P < 0.05; **P < 0.005 (control vs. inhibitors).
the highly conserved C 924 and W 926 PASK residues to alanine resulted in a significantly weakened interaction with Wdr5. As these residues are adjacent to the mTORC1 phosphorylation site on PASK (Fig. 6C) , we hypothesized that mTORC1-mediated PASK phosphorylation might augment Wdr5 binding. Indeed, we found that the TS [5] A mutant, lacking mTORC1-mediated phosphorylation, failed to show Rheb Q64L -dependent induction of the interaction between PASK and Wdr5 (Fig. 6E) . Taken together, these data suggest that mTORC1-mediated phosphorylation of PASK stimulates the PASK-Wdr5 association. We have shown previously that this interaction correlates strongly with PASK phosphorylation of Wdr5 at Ser 49 , which orchestrates epigenetic changes at the Myog promoter to enable gene expression. To test if Wdr5 phosphorylation at Ser 49 by PASK is a mechanism whereby mTORC1 signals to induce myogenesis, we first tested whether expression of the phosphomimetic Wdr5 mutant (Wdr5 S49E ) might rescue the defect in myogenesis resulting from mTORC1 inhibition. As shown in Fig. 6F , rapamycin completely prevented the induction of Myog and Mylff in response to differentiation cues. These defects were completely reversed by expression of the phosphomimetic Wdr5 mutant Wdr5 S49E , while the expression of Wdr5 WT or Wdr5 S49A had no effect (Fig. 6F) . Consistent with the mRNA data, Western blot analysis showed that Wdr5 S49E , but not Wdr5 S49A , also restored MyoG and MHC protein induction in rapamycin-treated cells (Fig. 6G) . Intriguingly, while the expression of Wdr5 S49E rescues the MyoG expression (Fig. 6 F and G) , it does not appear to completely rescue the rapamycin-inhibited myoblast fusion program (Fig. 6 H and I) . The myotubes are smaller and thinner and have fewer myonuclei in Wdr5 S49E -expressing cells in rapamycin-treated cells compared with DMSO-treated samples ( Fig. 6H and quantified in Fig. 6I ). This result is consistent with our data that mTOR-PASK signaling is required for efficient MyoG induction (which is rescued by Wdr5 S49E ), whereas mTOR-S6K1 signaling is required for an efficient myoblast fusion program (only partially rescued by Wdr5 S49E ). Taken together, our results have identified a signaling pathway that transmits nutrient and hormonal signals via mTORC1 phosphorylation and activation of PASK to induce Myog expression and commitment to differentiate through phosphorylation of the Wdr5 epigenetic regulator (Fig. 7) and shows functional partitioning of the mTORC1 function during myogenesis. Discussion mTORC1 integrates multiple signals from the regenerating niche, including nutrients as well as hormones, such as insulin, IGF1, or Wnt, and is required for myogenesis and muscle growth and hypertrophy. In this study, we show that PASK is a substrate of mTORC1 downstream of these same niche signals, particularly insulin and nutrients. mTORC1-dependent phosphorylation and activation of PASK activate Myog transcription, and thereby establish the commitment to myogenic differentiation (Fig. 7) . mTORC1 activation of p70S6K simultaneously activates the protein synthesis that is required for rapid myotube hypertrophy, resulting in the culmination of the myogenesis program. Thus, mTORC1 coordinately enables both aspects of myogenesis via activation of distinct protein kinase signaling pathways. mTORC1, PASK, and Wdr5 are widely expressed in stem cells. As PASK is required for the differentiation of multiple stem cell lineages (21) , this model could represent a common mechanism by which nutrient and hormonal signaling could establish the commitment to differentiate via mTORC1 signaling. This might be particularly relevant for cell types that are highly metabolically active, like muscle cells and adipocytes (36) .
The role of the mTOR protein kinase in the regulation of myogenesis appears to be multidimensional (14) . mTOR has been shown to regulate the myogenesis program using two different mechanisms, only one of which depends upon its catalytic activity (14, 35) . Moreover, mTOR not only regulates the early stages of myogenesis but also controls the remodeling of myotubes after differentiation (16, 37) . Despite considerable interest, it remains unclear how mTOR signals to establish the early steps of myogenic commitment in MuSCs. Multiple genetic studies and our data (shown in Fig. 4E ) suggest the requirement of the raptor-containing mTORC1, but not the rictor-containing mTORC2, to mediate the early steps of myogenic commitment (17, 19, 20, 38, 39) . One of the major substrates of mTORC1, p70S6K1, is dispensable for the early steps of the myogenesis program (14, 40) (Fig. 4E) . S6K1 or S6K2, however, plays an important role in myotube remodeling. Our results suggest that PASK may be the missing downstream effector of mTORC1 signaling that initiates myogenesis. mTORC1 phosphorylates PASK within two distinct regions: the N-terminal residues T 640 and T 642 and the C-terminal residues S 949 , S
953
, and S 956 . These residues are highly conserved, suggesting the possible conservation of mTORC1-PASK signaling across metazoan species. Interestingly, similar to what is observed for several other mTORC1 substrates, the two regions of PASK sites have variable rapamycin sensitivity. Consistent with being more robust sites, phosphorylation at S 949 , S
, and S 956 is resistant to rapamycin. These sites are adjacent to the Wdr5 binding motif, and we showed that phosphorylation augments PASK interaction with Wdr5, and presumably activation of myogenic gene expression. It remains unclear what role phosphorylation of the N-terminal residues plays in PASK. However, it is noteworthy that rapamycin-mediated inhibition of mTORC1, while not sufficient to block all in vivo phosphorylation of PASK (SI Appendix, Fig. S2 A and B) , is sufficient to block an amino acid-and insulin-dependent increase in PASK activity ( Fig. 1 C and D) . Thus, two islands of mTORC1 phosphorylation sites on PASK may have a slightly distinct functional role. It is possible that due to the juxtaposition of these sites to the N-terminal PAS domain of PASK, they may impact the intramolecular interaction between PAS and the kinase domains (41) and regulate PASK catalytic activity. On the other hand, the juxtaposition of C-terminal sites to the Wdr5 binding region may regulate interactions between PASK and Wdr5. Thus, mTORC1 might function to integrate nutrient and hormonal signals to increase PASK activity and Wdr5 phosphorylation to coordinate myogenesis via multisite phosphorylation.
PASK expression was induced several-fold during regenerative myogenesis as early as day 3 postinjury and coincides with the induction of Myog expression (17) . Our data presented here suggest that mTORC1-mediated posttranslational activation of PASK might provide another layer of control over the critical decision of commitment to differentiate. We propose that such precise signaling control of the epigenetic network is required to regulate myogenesis in accordance with the environmental status. As such, multiple pharmacological and genetic approaches have established that hyperactivation of PI3K/mTORC1 signaling leads to MuSC exhaustion and exacerbates age-associated muscle wasting, presumably due to premature myogenesis and loss of self-renewal potential. Similarly, we show that overexpression of WT PASK (Fig. 5 A-D and SI Appendix, Fig. S1B ) or Wdr5 S49E is sufficient to activate the myogenesis program even in the absence of differentiation signaling. Thus, we propose that PASK activity and expression are both controlled to prevent the precocious differentiation of MuSCs. By integrating nutrient information with epigenetic changes via Wdr5 phosphorylation, mTORC1-PASK signaling can precisely and appropriately control the myogenesis program.
Materials and Methods
Cell Lines and Treatments. HEK293E, HEK293T, and C2C12 myoblasts were obtained from the American Type Culture Collection (ATCC). Parental Tsc2 −/− and hTsc2-complemented MEFs were a gift from Brendan Manning, DanaFarbar Harvard Cancer Center, Massachusetts, Boston. These cells were all cultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. For amino acid stimulation, custom DMEM was ordered from Invitrogen to lack L-leucine or L-leucine and L-arginine. For all nutrient and insulin stimulation experiments, C2C12 cells, HEK293E cells, or MEFs were used, as these cells respond to insulin, and were prepared as described in SI Appendix, Extended Methods and Material. HEK293T cells were used for an experiment involving Rheb Q64L overexpression. All cells were routinely checked for the presence of mycoplasma and were karyotyped by the ATCC. All cells were kept at 37°C with 5% CO 2 .
Isolation of Primary Myoblasts. MuSCs were isolated from 10-to 12-wk-old WT and PASK −/− littermates according to published protocols (42) .
Briefly, TA muscles from hind limbs of WT or PASK −/− mice were isolated, minced in DMEM, and enzymatically digested with 0.1% Pronase for 1 h. After repeated trituration, the cell suspension was filtered through a 100-μM filter. Cells were plated on Matrigel-precoated plates and allowed to grow for 4 d. The differentiation of these MuSC-derived myoblasts was stimulated by the addition of 100 nM insulin in serumfree DMEM.
Cell Lysis and Immunoprecipitation. For immunoprecipitation, cells were lysed in a native lysis buffer containing 40 mM Hepes (pH 7.4), 150 mM NaCl, 2 mM KCl, 1 mM EDTA, 1 mM EGTA, 100 mM sodium pyrophosphate, 10 mM β-glycerophosphate, and protease and phosphatase inhibitor mixtures. Lysates were incubated on ice for 15 min, followed by high-speed centrifugation to pellet insoluble debris. The soluble fraction was subjected to immunoprecipitation using the antibodies as indicated. For mTOR-PASK coimmunoprecipitation experiments, cells were lysed in mTOR lysis buffer as described in SI Appendix, Extended Methods and Material.
In Vitro Kinase Assay. The in vitro kinase assays for PASK were performed as described previously (21, 22) . Briefly, endogenous or overexpressed PASK was purified from cells using an anti-PASK antibody or anti-V5 antibody utilizing a native cell lysis buffer as described above. SDS sample buffer. For mTORC1, an in vitro kinase assay was performed as described in SI Appendix, Extended Methods and Material using purified Flag-raptor + mTOR complex and purified KD PASK.
Metabolic in Vivo Labeling. Metabolic in vivo labeling was performed in cells expressing various PASK plasmids with or without constitutively active Rheb (Rheb Q64L ). Twenty-four hours after transfection, cells were washed twice with phosphate-free DMEM (Invitrogen), followed by incubation with 1.0 mCi of 32 P. Cells were washed with phosphate-free DMEM to remove unincorporated 32 P, lysed using lysis buffer, and immunoprecipitated as described above. Immunocomplexes were washed with buffer (20 mM Na 2 HPO 4 , 0.5% Triton X-100, 0.1% SDS, 0.02% NaN 3 ) containing high salt (1 M NaCl, 0.1% BSA) followed by low salt (150 mm NaCl) in the same buffer. Immunoprecipitated PASK was released by SDS/PAGE sample loading buffer and separated by SDS/PAGE, followed by transfer to nitrocellulose membranes and autoradiographic imaging.
Immunofluorescence Microscopy. Primary myoblasts (isolated from Rosa26 hPASK-V5 or WT mice) or C2C12 myoblasts growing on coverslips were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and incubated with the respective primary antibodies overnight in a humidified chamber as described in Materials and Methods. Corresponding fluorescence-conjugated secondary antibodies were added for 1 h, followed by mounting coverslips on frosted slides in mounting media containing DAPI. Image quantification and analysis were performed as described in SI Appendix, Extended Methods and Material.
